Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caffeic Acid SCHEMBL7790614 | 0.85 | CCR5 (0.49) | POLBALOX5LMNAATMNFKB1 | |
| SCHEMBL7368806 | 0.75 | POLB (0.79) | POLBFFAR1ALDH1A1PKM | |
| SCHEMBL30792366 | 0.75 | FFAR1 (0.81) | POLBFFAR1LMNANFKB1NFKB2 | |
| SCHEMBL274471 | 0.75 | FFAR1 (0.81) | POLBFFAR1LMNANFKB1NFKB2 | |
| SCHEMBL21317665 | 0.74 | POLB (1.00) | POLBFFAR1ALDH1A1PKM | |
| SCHEMBL21317651 | 0.74 | POLB (0.58) | POLBFFAR1NFKB1GAAALDH1A1 | |
| SCHEMBL26046352 | 0.74 | POLB (0.45) | POLBFFAR1FFAR4KEAP1ALDH1A1 | |
| SCHEMBL10893098 | 0.72 | USP2 (0.48) | POLBATMLDHAF2RL1ALDH1A1 | |
| SCHEMBL21317652 | 0.72 | POLB (0.59) | POLBFFAR1NFKB1GAAALDH1A1 | |
| SCHEMBL503646 | 0.72 | ALOX5 (0.68) | FFAR1ALOX5FFAR4F2RL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | AB, Medivir (SE) | 2002-09-12 | — | — | US | disclosed |
| EP-1121366-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999051613-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | POLB 49/4885FFAR1 1986/4885ALOX5 1324/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | POLB 1463/4885FFAR1 1069/4885ALOX5 3919/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | POLB 49/4885FFAR1 1986/4885ALOX5 1324/4885 |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, CBR1, GAR1 | POLB 322/4885FFAR1 259/4885ALOX5 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.